KR20120004488A - 정신분열증의 치료를 위한 2,4,6-트리아미노-1,3,5-트리아진 유도체를 포함하는 조성물 - Google Patents

정신분열증의 치료를 위한 2,4,6-트리아미노-1,3,5-트리아진 유도체를 포함하는 조성물 Download PDF

Info

Publication number
KR20120004488A
KR20120004488A KR1020117025603A KR20117025603A KR20120004488A KR 20120004488 A KR20120004488 A KR 20120004488A KR 1020117025603 A KR1020117025603 A KR 1020117025603A KR 20117025603 A KR20117025603 A KR 20117025603A KR 20120004488 A KR20120004488 A KR 20120004488A
Authority
KR
South Korea
Prior art keywords
lower alkyl
substituted
aryl
schizophrenia
pharmaceutically acceptable
Prior art date
Application number
KR1020117025603A
Other languages
English (en)
Korean (ko)
Inventor
신지 다까하시
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20120004488A publication Critical patent/KR20120004488A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117025603A 2009-03-31 2010-03-30 정신분열증의 치료를 위한 2,4,6-트리아미노-1,3,5-트리아진 유도체를 포함하는 조성물 KR20120004488A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2660962A CA2660962A1 (fr) 2009-03-31 2009-03-31 Nouvelle composition pharmaceutique pour le traitement de la schizophrenie
CA2660962 2009-03-31

Publications (1)

Publication Number Publication Date
KR20120004488A true KR20120004488A (ko) 2012-01-12

Family

ID=42269730

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117025603A KR20120004488A (ko) 2009-03-31 2010-03-30 정신분열증의 치료를 위한 2,4,6-트리아미노-1,3,5-트리아진 유도체를 포함하는 조성물

Country Status (7)

Country Link
EP (1) EP2413940A1 (fr)
JP (1) JP2012521963A (fr)
KR (1) KR20120004488A (fr)
CN (1) CN102378630A (fr)
CA (1) CA2660962A1 (fr)
TW (1) TW201035081A (fr)
WO (1) WO2010114163A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170002980U (ko) 2016-02-16 2017-08-24 주식회사 마르시끄 일회용 마스카라

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103351348A (zh) * 2013-07-15 2013-10-16 黄河三角洲京博化工研究院有限公司 一种2-甲胺基嘧啶盐酸盐的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1982799A (en) 1998-01-23 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein
KR100947185B1 (ko) 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
US7375222B2 (en) * 2002-02-05 2008-05-20 Astellas Pharma Inc. 2,4,6-Triamino-1,3,5-triazine derivative
JP2010524434A (ja) * 2007-03-26 2010-07-22 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｋｃｎｈ２の統合失調症関連アイソフォームおよび抗精神病薬の開発

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170002980U (ko) 2016-02-16 2017-08-24 주식회사 마르시끄 일회용 마스카라

Also Published As

Publication number Publication date
WO2010114163A1 (fr) 2010-10-07
TW201035081A (en) 2010-10-01
JP2012521963A (ja) 2012-09-20
CN102378630A (zh) 2012-03-14
CA2660962A1 (fr) 2010-09-30
EP2413940A1 (fr) 2012-02-08

Similar Documents

Publication Publication Date Title
CN104302295B (zh) 用tor 激酶抑制剂治疗癌症
US20210023043A1 (en) Methods of Treating Hyperalgesia
JP7377548B2 (ja) 抗精神病薬及びその用途
CN108472285A (zh) 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
CN111788182B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CA2681267C (fr) Agents anti-angiogeniques et procedes d'utilisation
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
KR20200081424A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
KR20160093686A (ko) 벤즈이미다졸-프롤린 유도체의 용도
JP2020526557A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
US20210163406A1 (en) Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
CA2844091A1 (fr) Analogues de quinazolinone et utilisation d'analogues de quinazolinone pour le traitement ou la prevention de certaines infections virales
JP2022501417A (ja) イオンチャネル阻害化合物を使用して過敏性咳またはかゆみを治療する方法
KR20120004488A (ko) 정신분열증의 치료를 위한 2,4,6-트리아미노-1,3,5-트리아진 유도체를 포함하는 조성물
CA2814828C (fr) Procede de traitement de troubles mentaux
US20100256152A1 (en) Novel pharmaceutical composition for treatment of schizophrenia
CN113754580B (zh) 一种吡啶吗啉类化合物、其制备方法及其应用
US20120088772A1 (en) Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder
BRPI0901286A2 (pt) nova composição farmacêutica para o tratamento da esquizofrenia
AU2009201338A1 (en) Novel pharmaceutical composition for treatment of schizophrenia
US20230255933A1 (en) Antiviral use of fabp4 modulating compounds
US20200392126A1 (en) Isoxazolyl compounds as receptor modulating compounds and methods and uses thereof
CA3171335A1 (fr) Monotherapies et polytherapies avec des inhibiteurs de ulk1/2
CA3222586A1 (fr) Inhibiteurs de ttbk1
CA3181979A1 (fr) Espece d'alpha-synucleine aberrante ciblee et ubiquitination induite et clairance proteosomique par co-recrutement d'un systeme e3-ligase